New Discoveries in Cancer and Heart Disease
ABOUT VASOCELL
The discovery of MCED and all subsequent insights are the work of Larry Weisenthal, M.D., Ph.D. Dr. Weisenthal operates a laboratory-based medical oncology practice. His practice focuses on identifying personalized chemotherapy treatments that afford individual cancer patients the highest probability of clinical benefit. In this work, Dr. Weisenthal applies a laboratory test called the DiSC assay, which he originated. The DiSC Assay, more generally known to physicians and researchers as the Weisenthal Assay, has been called the “gold standard” by experts in the field. The DiSC/Weisenthal assay has been used to select therapy for thousands of cancer patients worldwide. (www.weisenthalcancer.com)
Dr. Weisenthal’s laboratory and research staff includes 3 laboratory technicians and two administrative coordinators.
Dr. Weisenthal is board-certified in internal medicine and medical oncology. In addition to his medical degree Dr. Weisenthal holds a Ph.D. in pharmacology research and is Clinical Professor of Medicine, (Hematology/Oncology), at University of California Irvine School of Medicine.
Throughout his career, Dr. Weisenthal has conducted innovative cancer research. He regularly publishes in peer-reviewed medical journals and presents at medical meetings and symposia. (Click here for Dr. Weisenthal's bibliography).
Curriculum Vitae
Larry Mark Weisenthal, M.D., Ph.D.
16512 Burke Lane
Huntington Beach, CA 92647
Citizenship
USA
Current Positions
Medical and Laboratory Director
Weisenthal Cancer Group
Huntington Beach, CA
www.weisenthalcancer.com
Research Director
MCED VasoCell
Huntington Beach, CA
www.vasocell.com
Clinical Professor of Medicine
Hematology/Oncology
University of California, Irvine
School of Medicine
Irvine, CA
Certification Boards
American Board of Internal Medicine
Certified, Medical Oncology
Medical License
California G 041204
Undergraduate Education
University of Louisville
Louisville, KY
Undergraduate chemistry major
B.A. equivalent - entered medical school after 3 years
Medical Education
University of Michigan
Ann Arbor, MI
M.D.
Graduate Education
University of Michigan
Ann Arbor, MI
Ph.D. Pharmacology
Laboratory of Raymond W. Ruddon, MD, PhD
Post Graduate Education
Residency
Internal Medicine
University Hospital
Ann Arbor, MI
Post-Doctoral Fellowship
Medical Oncology Clinical Associate
National Cancer Institute, Bethesda, MD
Medicine Branch/COP/DCT/NCI
Post-Doctoral Research
National Cancer Institute / National Institutes of Health
Bethesda, MD:
Laboratory of Marc E. Lippman, MD
Military Service
U.S. Public Health Service
Surgeon Grade (Lt. Commander)
Positions Held
Instructor (Pharmacology),
University of Michigan
Staff Physician, Section Hematology/Oncology,
Veterans Administration Medical Center
Long Beach, CA
Assistant Professor in Residence
Department of Medicine
University of California Irvine
Irvine, CA
Clinical Investigator
Veterans Administration Central Office
Career Development Program
Long Beach, CA
Associate Professor in Residence
Department of Medicine
University of California Irvine
Irvine, CA
Associate Adjunct Professor
Department of Medicine
University of California Irvine
Irvine, CA
Founder, Founding Corporate Director, Laboratory Director, Vice-President for Scientific Affairs
Oncotech, Inc.
Irvine, CA
Government Service
Advisory/Site Visit Committee for National Cancer Institute
Cell Culture New Drug Screening Program
National Oncology Reviewer
Veterans Administration National Research Advisory Group
Biographical Sketch
Larry Weisenthal M.D., Ph.D. received his undergraduate education at the University of Louisville where he was chosen Outstanding Freshman, Sophomore, and Junior Man, successively, by the faculty in the years he attended.
After three years as an undergraduate at Louisville, Dr. Weisenthal received a scholarship to the University of Michigan Medical School, where he earned his M.D. degree. Also at Michigan, he earned a separate Ph.D. degree, in Pharmacology.
Following a residency at the University of Michigan Medical Center and board certification in Internal Medicine, Dr. Weisenthal completed a post doctoral fellowship at the National Cancer Institute, in Bethesda, Maryland, where he was Clinical Associate in the Medicine Branch, earning additional board certification in Medical Oncology.
At this time, he also began a six year term of duty as Lieutenant Commander in the U.S. Public Health Service.
While at the NCI, Dr. Weisenthal began research in the area of Personalized Medicine, ultimately leading to his developing a laboratory test to aid in individualizing chemotherapy for cancer patients based upon anti-tumor activity of candidate drugs against each patient’s own living tumor cells. Dr. Weisenthal’s test has been called the “gold standard” by researchers in the field. The test itself and also the “cell death” endpoint upon which it is based (this endpoint was also originated by Dr. Weisenthal) have been adopted by laboratories worldwide, supplanting older, less effective methods.
Following a cancer research and medical oncology staff appointment at the Long Beach Veteran’s Administration Medical Center, in Long Beach, California, Dr. Weisenthal co-founded Oncotech, a laboratory company focused on helping physicians nationwide to individualize chemotherapy selection for cancer patients. The company was later acquired by Ecxiqon.
In 1992, Dr. Weisenthal founded the Weisenthal Cancer Group which combines a commercial laboratory facility in Huntington Beach, California, owned and operated by Dr. Weisenthal, with his laboratory-based medical oncology practice. Tumor cells obtained through biopsy from individual cancer patients are tested for susceptibility to a wide range of chemotherapy agents. Dr. Weisenthal then uses information from the laboratory tests to make personalized chemotherapy recommendations to the patients’ cancer physicians. Dr. Weisenthal’s physician client base is worldwide.
Dr. Weisenthal holds an academic appointment as Associate Clinical Professor of Medicine at the University of California Irvine.
He has served on numerous boards and panels including the Editorial Advisory Board of the Journal of the National Cancer Institute and the Advisory Panel to the New Drug Discovery Program of the National Institutes of Health.
He also served and as National Oncology Research Grant Reviewer for the U.S. Veteran’s Administration.
Dr. Weisenthal has been an invited lecturer at numerous medical meetings, seminars, and symposia in the U.S., Europe, and Asia. He is author of more than 100 published articles, abstracts, and textbook chapters and is co-editor of an oncology textbook.
“The discovery of circulating MCED truly is a case of opportunity meeting the prepared mind. Thirty-five years of full-time cellular research and a lucky set of circumstances led to the breakthrough.”